Table 1 Baseline characteristics
Characteristic | Number of patients (%) |
|---|---|
Age (years) | |
Median (range) | 71 (51–87) |
Gleason score | |
≤ 6 | 55 (22.4) |
7 | 96 (39.0) |
8 | 51 (20.7) |
9 | 37 (15.0) |
10 | 7 (2.8) |
PSA before treatment (ng/ml) | |
Median (range) | 31.8 (1.14–2376) |
≤ 10 | 35 (14.2) |
10–20 | 53 (21.5) |
> 20 | 158 (64.2) |
Clinical T stage | |
T1 | 15 (6.1) |
T2 | 125 (50.8) |
T3 | 82 (33.3) |
T4 | 24 (9.8) |
NCCN risk group | |
Low risk | 6 (2.4) |
Intermediate risk | 49 (19.9) |
High risk | 100 (40.7) |
Locally advanceda | 49 (19.9) |
N1b | 42 (17.1) |
ADT duration (months) | |
Median (range) | 31 (1–154) |
≤ 6 months | 22 (8.9) |
> 6 and ≤ 12 months | 30 (12.2) |
> 12 and ≤ 24 months | 49 (19.7) |
> 24 and ≤ 36 months | 81 (32.9) |
> 36 months | 58 (23.6) |
Irradiation field | |
Prostate + seminal vesicles | 110 (44.7) |
Prostate + seminal vesicles + pelvic lymph node | 103 (41.9) |
Prostate + seminal vesicles + pelvic lymph node + residual pelvic lymph node boost | 33 (13.4) |
Pelvic lymph node boost dose | |
60 Gy/2.4 Gy/25f | 10 (4.0) |
62.5 Gy/2.5 Gy/25f | 2 (0.8) |
65 Gy/2.6 Gy/25f | 2 (0.8) |
67.5 Gy/2.7 Gy/25f | 19 (7.7) |